Gleevec Marked a Turning Point in Cancer Treatment 23 Years Ago
The Food and Drug Administration (FDA) approved Gleevec for leukemia treatment in 2001, marking a new phase in cancer care. The drug offered a targeted treatment, improving survival rates and quality of life for patients.
Advertisement
In 2001, the Food and Drug Administration (FDA) approved Gleevec for treating chronic myeloid leukemia (CML), signaling a transformation in cancer treatment. Gleevec, also known as imatinib, provided a targeted therapy option.
Traditional cancer treatments like chemotherapy often affect healthy cells along with cancerous ones. Gleevec, in contrast, targets a specific protein produced by CML cells. This protein drives the uncontrolled growth characteristic of the disease.
Dr. Brian Druker, director of the Knight Cancer Institute at Oregon Health & Science University, championed Gleevec's development.
Before Gleevec, CML patients faced limited treatment options, including stem cell transplants and interferon therapy. Both treatments carried significant risks and side effects.
Gleevec offered patients a pill form of medication, improving survival rates and quality of life. The treatment's success spurred research into similar targeted therapies for other cancers, changing expectations for cancer treatments.
Related Topics
Article Ratings
How do you feel about this story?
National Desk
Sign in to follow this author from their profile.
Discussion (0)
Join the Conversation
Join the conversation
Sign in to share your thoughts, reply to readers, and like comments.
No comments yet. Be the first to comment!